FPÖ warns: Government hands over health policy to the WHO!

FPÖ warns: Government hands over health policy to the WHO!

Österreich - On July 9, 2025, the FPÖ treated a change in the WHO international health regulations (IGV) in parliament. The FPÖ petition spokeswoman NABG said. Marie-Christine Giuliani-Sacher criticism of unqualified statements about Ivermectin, a medication whose developer received the Nobel Prize. It emphasized the importance of the dosage for the effect of medication and expressed concerns about the communication of the government regarding Corona vaccination and its possible side effects.

Giuliani locker called for more personal responsibility and honest information for the population and criticized the government to transfer further powers to the WHO. In this context, the SPÖ Minister of Health was described as inadequate as a profession, since she comes from the union. In addition, Giuliani barrier warned of possible conflicts of interest by lobbyists from the pharmaceutical industry and asked why Austria took over the IGV change without resistance, while other countries wait.

The situation around Ivermectin

Current evidence of the use of Ivermectin for the treatment of COVID-19 patients have been rated by the WHO as not conclusive. [WWHO] recommends using the medication only as part of clinical studies. This applies to COVID-19 patients with light as well as with severe symptoms. Ivermectin is a proven ant parasitic means and is on the list of the essential medication of the WHO for various parasitic diseases.

The WHO has called up an expert group to take into account the increased international attention for Ivermectin. This group checked data from 16 randomized controlled studies with 2407 patients and found that the evidence of the effectiveness of evermectin in Covid-19 is "very low security". This is due to the small size and the methodological restrictions on the studies. The WHO recommendations also include that the use of therapeutic agents such as systemic corticosteroids and low -dose anticoagulants is recommended in certain situations, while other medications such as hydroxychloroquin or lopinavir/ritonavir are recommended.

warnings and concerns about Ivermectin

The Federal Office of Health Care (BASG) warned in March 2021 about the application of Ivermectin for the treatment of COVID-19, and this warning remains. According to [Gesundheits.gv.at], the European Pharmaceutical Agency (EMA) also expresses concerns about the application of Ivermectin for Covid-19. In Austria, Ivermectin is approved for many animal species to combat internal and external parasites.

In humans, it is used to treat skabies and parasitic worms. Clinical studies have shown inconsistent results, with some of them showing no benefits and others. The EMA has repeatedly stated that the use of Ivermectin outside of controlled clinical studies cannot be recommended. There were also risks regarding serious side effects for higher doses than the approved.

The virologist Christoph Steininger warns against the use of Ivermectin for the treatment of Covid-19, as it is classified as risky due to a lack of approval and proof of effects. Controlled research of active ingredients is crucial for the development of new or improved medicines and must not be undermined.